UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or ? TRANSITION REPORT PURSUANT TO...
2026 Q2 Form 10-Q
Filed with ASX · · 46 pages · English
Summary by 6ix AI
The report includes unaudited condensed consolidated financial statements, which reflect the company's revenues, expenses, and net loss for the quarter. Overall, the filing aims to inform investors about the company's financial health and operational results during the specified period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/2026-q2-form-10-q
Release
Imricor Medical Systems, Inc. on 6ix
Earlier from Imricor Medical Systems
- Q2 CY2026 Quarterly Activities Report & Form 10-Q Submission
- Philips Declares Compatibility with Imricor
- Q2 FY26 Results Webinar Notification
Later from Imricor Medical Systems
- 1H 2026 Investor Presentation
- Imricor U.S. Commercial Momentum Accelerates
- Imricor and Philips Launch Commercial iMR Lab Solution
- Release from Voluntary Escrow
- FDA Accepts Imricor PMA Manufacturing Module
Follow Imricor Medical Systems into a list and get an email when it puts out news.
Follow Imricor Medical Systems